TP53 and small cell lung carcinoma: Many malignancies are associated with somatic mutations in TP53 [1–3], including small cell lung cancer (SCLC), which has an extremely poor prognosis despite frequent initial responses to the standard, first-line, platinum-doublet chemotherapy [4–11].